Levanat S, Pavelić K
Ruder Bosković Institute, Zagreb, Yugoslavia.
Biol Chem Hoppe Seyler. 1990 Mar;371(3):249-54. doi: 10.1515/bchm3.1990.371.1.249.
A substance immunologically cross-reactive with insulin (SICRI) appears in murine myeloid leukemia. Progression of disease is paralleled by the increase of SICRI levels in the serum; this increase of SICRI levels did not correlate with a decreased concentration of circulating glucose. SICRI was isolated and purified from spleen infiltrated with leukemic cells. Monospecific antiinsulin immunoglobulin G was used for immunoaffinity chromatography to isolate SICRI from tumor tissue. The purified substance yielded a single band with a molecular mass of about 150 kDa in polyacrylamide gel electrophoresis under denaturating and non-denaturating conditions. Purified SICRI enhanced growth of myeloid leukemia cells in soft agar. Biochemical and biological data together with our previous results obtained in other experimental tumors provide evidence that SICRI and insulin are two distinct biologically active agents. SICRI plays a role in murine myeloid leukemia as an autocrine growth promoting factor.
一种与胰岛素发生免疫交叉反应的物质（SICRI）出现在小鼠髓性白血病中。疾病进展与血清中SICRI水平的升高平行；SICRI水平的这种升高与循环葡萄糖浓度的降低无关。SICRI是从浸润白血病细胞的脾脏中分离纯化出来的。使用单特异性抗胰岛素免疫球蛋白G进行免疫亲和层析，从肿瘤组织中分离SICRI。在变性和非变性条件下，纯化后的物质在聚丙烯酰胺凝胶电泳中产生一条分子量约为150 kDa的单一条带。纯化的SICRI可增强软琼脂中髓性白血病细胞的生长。生化和生物学数据以及我们之前在其他实验性肿瘤中获得的结果共同提供了证据，表明SICRI和胰岛素是两种不同的生物活性剂。SICRI作为一种自分泌生长促进因子在小鼠髓性白血病中发挥作用。
